Introduction - Orl-nko
... Physiotherapy, cervical manipulation, vestibular training or repositioning maneuvers (to be precised) ...
... Physiotherapy, cervical manipulation, vestibular training or repositioning maneuvers (to be precised) ...
Regional Anesthesia in the Patient with Preexisting Neurologic
... Patients with preexisting intracranial masses and vascular lesions such as primary or metastatic brain tumors, saccular aneurysms, or arteriovenous malformations are at increased risk for neurologic compromise during spinal or epidural anesthesia. Alterations in intracranial pressure and mean arteri ...
... Patients with preexisting intracranial masses and vascular lesions such as primary or metastatic brain tumors, saccular aneurysms, or arteriovenous malformations are at increased risk for neurologic compromise during spinal or epidural anesthesia. Alterations in intracranial pressure and mean arteri ...
Epley Maneuver in Vertigo
... (Auagnostou et al,. 2013). The results of the study indicate that the Epley maneuver is an effective therapy to implement in order to treat BPPV. Strengths and opportunities of this study were that the Epley maneuver is an effective option to use when treating BPPV and that it is just as effective a ...
... (Auagnostou et al,. 2013). The results of the study indicate that the Epley maneuver is an effective therapy to implement in order to treat BPPV. Strengths and opportunities of this study were that the Epley maneuver is an effective option to use when treating BPPV and that it is just as effective a ...
Tysabri® (natalizumab) and Lemtrada™ (alemtuzumab) (IV Multiple
... Natalizumab is generally reserved for patients who have failed to respond to first line agents or for patients who have very progressive disease. Labeling for alemtuzumab supports its use by a neurologist experienced in RRMS after failure of interferon beta or other disease modifying therapies.13, 1 ...
... Natalizumab is generally reserved for patients who have failed to respond to first line agents or for patients who have very progressive disease. Labeling for alemtuzumab supports its use by a neurologist experienced in RRMS after failure of interferon beta or other disease modifying therapies.13, 1 ...
Dept of Radiology and Neurology Penn State Milton S
... Introduction: AD is the most common cause of dementia and the prevelance by 2050 will be more than triple. Currently, the diagnosis of AD relies upon clinical neurological assessment combined with CT or MRI to exclude other potential etiologies for the patient's dementia. Pathology: Brain atrophy wi ...
... Introduction: AD is the most common cause of dementia and the prevelance by 2050 will be more than triple. Currently, the diagnosis of AD relies upon clinical neurological assessment combined with CT or MRI to exclude other potential etiologies for the patient's dementia. Pathology: Brain atrophy wi ...
Biological Treatments for depression (PPH) 2011
... The most serious side-effects usually associated with Prozac are fainting and an irregular/fast heartbeat. Allergic reactions to Prozac are unlikely but include rash, itching, swelling, dizziness and trouble breathing. ...
... The most serious side-effects usually associated with Prozac are fainting and an irregular/fast heartbeat. Allergic reactions to Prozac are unlikely but include rash, itching, swelling, dizziness and trouble breathing. ...
Phantosmia
Phantosmia is an olfactory hallucination. A hallucination is the sensory perception of something with no basis in reality, as opposed to an olfactory illusion, which is a misinterpretation of a physical stimulus; in the case of an odor it is known as parosmia. Phantosmia is the perception of a smell in the complete absence of any physical odor. The perceived odor can range from pleasant to disgusting. Although the causes of phantosmia are uncertain, it often occurs with neurological and psychological disorders such as schizophrenia, mood disorders, Parkinsons disease, epilepsy, neuroblastoma, and frequent migraines.Galen also mentioned olfactory hallucinations in his work and stated that these hallucinations constitute the signs of an oncoming disease.Different types of phantosmia include: Unirhinal (single nostril), episodic, and recurrent, where the activation of brain's GABAergic system seems to play a role in the inhibition of the unirhinal phantosmia.Treatments for phantosmia range from drug therapies (e.g., venlafaxine) and brain stimulation therapies to invasive surgical procedures involving removal of the olfactory bulbs or olfactory epithelium.The word phantosmia is a noun of Greek origin. It is composed of two words: (1) phant- meaning ""phantom"" and (2) -osmia (from osme) meaning ""smell"".